#1 Clinical Trials Search in Europe

Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells

Recent clinical trials are investigating the potential of Allogeneic Skin-Derived ABCB5-Positive Dermal Mesenchymal Stromal Cells (ABCB5+ MSCs) in treating rare and challenging skin conditions. These trials focus on two main areas: epidermolysis bullosa (EB) and chronic venous ulcers (CVU). The studies aim to evaluate the safety and effectiveness of this innovative cell therapy in promoting wound healing and improving the quality of life for patients with these debilitating skin disorders.

Table of Contents

What are ABCB5-positive MSCs?

ALLOGENEIC SKIN-DERIVED ABCB5-POSITIVE DERMAL MESENCHYMAL STROMAL CELLS, also known as ABCB5+ MSCs, are a type of cell therapy being investigated for various medical conditions[1]. These cells are derived from human skin and have special properties that make them potentially useful in treating certain diseases. Let’s break down what this means:

  • Allogeneic: This means the cells come from a donor, not the patient themselves.
  • Skin-derived: The cells are obtained from skin tissue.
  • ABCB5-positive: These cells express a specific protein called ABCB5 on their surface, which helps identify them.
  • Dermal Mesenchymal Stromal Cells: These are a type of cell found in the deeper layer of the skin (dermis) that can develop into various cell types and have potential healing properties.

Potential Applications

Research is currently focusing on two main areas where ABCB5+ MSCs might be beneficial:

  1. Treating a rare genetic skin condition called Epidermolysis Bullosa (EB)
  2. Healing chronic venous ulcers (CVU), which are long-lasting wounds on the legs

Treatment for Epidermolysis Bullosa

Epidermolysis Bullosa (EB) is a group of rare genetic conditions that cause the skin to be very fragile and blister easily[1]. There are different types of EB, including Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bullosa (JEB). Currently, there’s no cure for EB, but researchers are studying whether ABCB5+ MSCs could help.

In a clinical trial, scientists are testing if these cells can help heal wounds in people with EB. They’re looking at things like:

  • How many patients have their wounds completely close after treatment
  • How quickly the wounds heal
  • Whether the treatment reduces pain and itching
  • If it improves overall quality of life for patients

Treatment for Chronic Venous Ulcers

Chronic venous ulcers (CVU) are open sores on the legs that don’t heal well, often due to poor blood circulation[2]. These ulcers can be painful and significantly impact a person’s quality of life. Researchers are investigating if ABCB5+ MSCs could help heal these stubborn wounds.

In a separate clinical trial, scientists are studying how well different doses of ABCB5+ MSCs work for treating CVUs. They’re looking at:

  • How many patients have their ulcers completely heal
  • How quickly the ulcers close
  • Whether the treatment reduces pain
  • If it improves overall quality of life for patients

Administration and Dosage

The way ABCB5+ MSCs are given to patients depends on the condition being treated:

  • For Epidermolysis Bullosa: The cells are given through an intravenous (IV) injection into a vein[1].
  • For Chronic Venous Ulcers: The cells are applied directly to the wound as a cutaneous (skin) suspension[2].

The dosage varies depending on the condition and the specific clinical trial. For CVUs, researchers are testing different doses to find out which works best[2].

Safety and Efficacy

As with any new treatment, researchers are carefully monitoring the safety of ABCB5+ MSCs. They’re watching for any side effects or adverse reactions. Some specific things they’re checking include:

  • Development of antibodies against the treatment
  • Any signs of immune reactions
  • Overall survival of patients

It’s important to note that while these treatments show promise, they are still experimental. More research is needed to fully understand how well they work and if they’re safe for long-term use.

Ongoing Research

Clinical trials are currently underway to study ABCB5+ MSCs for both Epidermolysis Bullosa and chronic venous ulcers. These trials will help researchers understand:

  • How effective the treatment is
  • What the best dose might be
  • If there are any long-term effects
  • Which patients might benefit most from this treatment

As research continues, we may learn more about how ABCB5+ MSCs could potentially help people with these challenging conditions. However, it’s important to remember that clinical trials take time, and it may be several years before we know if this treatment will become widely available.

Aspect Epidermolysis Bullosa (EB) Trial Chronic Venous Ulcer (CVU) Trial
Trial Phase Phase III Phase IIb
Condition Recessive Dystrophic EB (RDEB) and Junctional EB (JEB) Chronic Venous Ulcers
Administration Method Intravenous Topical
Primary Endpoint Complete target wound closure at Month 6 Complete wound closure at Week 18
Key Secondary Endpoints Change in overall wound burden, pain severity, quality of life Wound size change, time to closure, quality of life
Patient Age From birth 18 years and older
Treatment Duration Multiple doses over 11 months Single application
Follow-up Period 17 months 18 weeks (efficacy), 10 months (safety)

FAQ

  • What are ABCB5-Positive Dermal Mesenchymal Stromal Cells? ABCB5-Positive Dermal Mesenchymal Stromal Cells (ABCB5+ MSCs) are a type of cell derived from human skin. These cells have special properties that may help in healing wounds and treating skin conditions. They are being studied as a potential treatment for rare skin disorders.
  • What conditions are being targeted in these clinical trials? The clinical trials are focusing on two main conditions: epidermolysis bullosa (EB), which includes recessive dystrophic and junctional forms, and chronic venous ulcers (CVU). Both of these conditions involve persistent wounds that are difficult to heal with current treatments.
  • How are the ABCB5+ MSCs administered in these trials? For the epidermolysis bullosa trial, the cells are administered intravenously (through a vein). In the chronic venous ulcer trial, the cells are applied topically (directly on the skin) to the wound area.
  • What are the main goals of these clinical trials? The main goals are to assess the safety of the treatment and to determine how effective it is in healing wounds. Researchers are looking at factors such as wound closure, reduction in wound size, pain levels, and overall quality of life for patients.
  • Who can participate in these clinical trials? Eligibility varies between the trials. For the EB trial, patients from birth with confirmed RDEB or JEB can participate. For the CVU trial, adults (18 years and older) with chronic venous leg ulcers that haven't healed despite standard treatments are eligible. Both trials have specific inclusion and exclusion criteria to ensure patient safety and study validity.

Ongoing Clinical Trials on Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells

  • Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Austria Croatia Denmark France Germany Greece +6

  • Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

    Not recruiting

    3 1
    Investigated drugs:
    Austria Czechia France Germany Hungary Italy +4

  • Study on the Effectiveness and Safety of allo-APZ2-CVU for Healing Chronic Venous Ulcers in Patients with Therapy-Resistant Wounds

    Not recruiting

    2 1
    Investigated drugs:
    Germany

Glossary

  • Epidermolysis Bullosa (EB): A group of rare genetic conditions that cause the skin to be very fragile and to blister easily. There are different types of EB, including recessive dystrophic (RDEB) and junctional (JEB) forms.
  • Chronic Venous Ulcer (CVU): A long-lasting sore on the leg or ankle that doesn't heal, usually caused by poor blood flow in the veins. These ulcers are considered chronic if they don't show signs of healing within 3 months despite treatment.
  • Mesenchymal Stromal Cells (MSCs): A type of cell found in various tissues that can develop into different cell types and has potential healing properties. In these trials, the MSCs come from skin and have a specific marker called ABCB5.
  • Intravenous Administration: A method of giving medication or other substances directly into a vein using a needle or tube.
  • Topical Application: Putting a medication or treatment directly onto the skin or affected area.
  • Placebo: A substance with no active medical effects, used in clinical trials to compare with the actual treatment being tested.
  • Efficacy: How well a treatment works to produce the desired result.
  • Adverse Event: Any unexpected or unwanted effect that occurs during a clinical trial, whether or not it's related to the treatment being studied.
  • Quality of Life: A measure of a person's overall well-being, including physical health, mental health, and ability to perform daily activities.
  • Randomized Trial: A type of clinical study where participants are randomly assigned to different treatment groups to compare outcomes.

References

  1. http://clinicaltrials.eu/trial/36922/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-allo-apz2-cvu-for-healing-chronic-venous-ulcers-in-patients-with-therapy-resistant-wounds/